Becton Dickinson Files 8-K on Officer Changes and Compensation
Ticker: BDX · Form: 8-K · Filed: Aug 30, 2024 · CIK: 10795
| Field | Detail |
|---|---|
| Company | Becton Dickinson & CO (BDX) |
| Form Type | 8-K |
| Filed Date | Aug 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $1.00 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, officer-changes
Related Tickers: BDX
TL;DR
BDX filed an 8-K detailing exec changes and pay. Keep an eye on leadership shifts.
AI Summary
Becton Dickinson & Co. (BDX) filed an 8-K on August 30, 2024, reporting changes in directors and officers, the election of new directors, and updates to compensatory arrangements for certain officers. The filing also includes financial statements and exhibits related to these corporate governance and compensation matters.
Why It Matters
Changes in corporate leadership and executive compensation can signal shifts in company strategy or performance, impacting investor confidence and stock valuation.
Risk Assessment
Risk Level: low — This filing primarily concerns corporate governance and executive compensation, which typically carries a lower immediate risk compared to financial distress or major operational disruptions.
Key Players & Entities
- BECTON DICKINSON & CO (company) — Filer
- BDX (company) — Ticker Symbol
FAQ
What specific changes were made regarding directors or officers?
The filing indicates changes related to the departure of directors or certain officers, the election of directors, and the appointment of certain officers.
Are there any updates to executive compensation arrangements?
Yes, the filing explicitly mentions 'Compensatory Arrangements of Certain Officers' as an item being reported.
What is the date of this filing?
The filing date is August 30, 2024.
What is Becton Dickinson's fiscal year end?
Becton Dickinson's fiscal year ends on September 30.
What is the company's primary business sector?
The company operates in the 'SURGICAL & MEDICAL INSTRUMENTS & APPARATUS' sector, with SIC code 3841.
Filing Stats: 568 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-08-30 16:16:36
Key Financial Figures
- $1.00 B — ch registered Common stock, par value $1.00 BDX New York Stock Exchange 1.900% No
Filing Documents
- dp217297_8k.htm (8-K) — 36KB
- 0000950103-24-012970.txt ( ) — 278KB
- bdx-20240830.xsd (EX-101.SCH) — 5KB
- bdx-20240830_def.xml (EX-101.DEF) — 28KB
- bdx-20240830_lab.xml (EX-101.LAB) — 39KB
- bdx-20240830_pre.xml (EX-101.PRE) — 27KB
- dp217297_8k_htm.xml (XML) — 11KB
02 Departure of Directors or Certain Officers; Election of
ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective August 30th, the following leadership change will take place. Thomas Spoerel will serve as the Senior Vice President, CFO Regions along with finance leadership for the finance integration of the recently announced agreement for Becton Dickinson to acquire the Edwards Life Sciences' Critical Care product group. Tom will no longer serve as the Company's principal accounting officer as set forth under Section 16 of the Securities Exchange Act of 1934, as amended, and Christopher DelOrefice, Executive Vice President and Chief Financial Officer, will assume the responsibilities of principal accounting officer on an interim basis.
01 Financial Statements and Exhibits
ITEM 9.01 Financial Statements and Exhibits. Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BECTON, DICKINSON AND COMPANY (Registrant) By: /s/ Gary DeFazio Gary DeFazio Senior Vice President and Corporate Secretary Date: August 30, 2024